메뉴 건너뛰기




Volumn 36, Issue 1, 1999, Pages 41-66

Clinical pharmacokinetics of lamivudine

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CIMETIDINE; COTRIMOXAZOLE; DIDANOSINE; DRUG METABOLITE; LAMIVUDINE; NUCLEOSIDE ANALOG; PROBENECID; RNA DIRECTED DNA POLYMERASE; STAVUDINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; ZALCITABINE; ZIDOVUDINE;

EID: 0032906981     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936010-00004     Document Type: Review
Times cited : (250)

References (70)
  • 1
    • 0025866982 scopus 로고
    • Anti-human immunodeficiency virus type I activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
    • 1. Soudeyns H, Yao XJ, Gao Q. et al. Anti-human immunodeficiency virus type I activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991; 35: 1386-90
    • (1991) Antimicrob Agents Chemother , vol.35 , pp. 1386-1390
    • Soudeyns, H.1    Yao, X.J.2    Gao, Q.3
  • 2
    • 0026541703 scopus 로고
    • The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro
    • 2. Coates JA, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992; 36: 202-5
    • (1992) Antimicrob Agents Chemother , vol.36 , pp. 202-205
    • Coates, J.A.1    Cammack, N.2    Jenkinson, H.J.3
  • 3
    • 0027431843 scopus 로고
    • The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine
    • 3. Skalski V, Chang CN, Dutschman G, et al. The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine. J Biol Chem 1993; 268: 23234-8
    • (1993) J Biol Chem , vol.268 , pp. 23234-23238
    • Skalski, V.1    Chang, C.N.2    Dutschman, G.3
  • 4
    • 0026740310 scopus 로고
    • Cellular metabolism of (-)-enantomeric 2′-deoxy-3′-thiacytidine
    • May 28
    • 4. Cammack N, Rouse P, Marr CLP, et al. Cellular metabolism of (-)-enantomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 1992 May 28; 43 (10): 2059-64
    • (1992) Biochem Pharmacol , vol.43 , Issue.10 , pp. 2059-2064
    • Cammack, N.1    Rouse, P.2    Marr, C.L.P.3
  • 5
    • 0003319295 scopus 로고    scopus 로고
    • Pharmacokinetics (PK) of lamivudine (3TC) phosphorylation on periopheral blood mammalian cells (PBMC) from HIV-infected patients
    • Jun 28-Jul 3: Geneva
    • th International Conference on AIDS; 1998 Jun 28-Jul 3: Geneva
    • (1998) th International Conference on AIDS
    • Moore, K.H.P.1
  • 6
    • 0026507919 scopus 로고
    • (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vilro
    • 6. Coates JA, Cammack N, Jenkinson HJ, et al. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vilro. Antimicrob Agents Chemother 1992: 36: 733-9
    • (1992) Antimicrob Agents Chemother , vol.36 , pp. 733-739
    • Coates, J.A.1    Cammack, N.2    Jenkinson, H.J.3
  • 7
    • 0026469165 scopus 로고
    • The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxanthiolan-5-y1] cytosine
    • 7. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxanthiolan-5-y1] cytosine. Antimicrob Agents Chemother 1992; 36: 2686-92
    • (1992) Antimicrob Agents Chemother , vol.36 , pp. 2686-2692
    • Furman, P.A.1    Davis, M.2    Liotta, D.C.3
  • 8
    • 0026697262 scopus 로고
    • Deoxycytidine deaminase-resistant stereoisomer is the active form of (-)-2′3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
    • 8. Chang C-N, Doong S-L, Zhou JH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (-)-2′3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 267: 13938-42
    • (1992) J Biol Chem , vol.267 , pp. 13938-13942
    • Chang, C.-N.1    Doong, S.-L.2    Zhou, J.H.3
  • 9
    • 0029028067 scopus 로고
    • Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
    • 9. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-9
    • (1995) Science , vol.269 , pp. 696-699
    • Larder, B.A.1    Kemp, S.D.2    Harrigan, P.R.3
  • 10
    • 0027285372 scopus 로고
    • Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
    • Jun 15
    • 10. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993 Jun 15; 90: 5653-6
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 5653-5656
    • Tisdale, M.1    Kemp, S.D.2    Parry, N.R.3
  • 11
    • 8944256865 scopus 로고    scopus 로고
    • Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
    • 11. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10: 975-81
    • (1996) AIDS , vol.10 , pp. 975-981
    • Kuritzkes, D.R.1    Quinn, J.B.2    Benoit, S.L.3
  • 12
    • 26844572356 scopus 로고    scopus 로고
    • 3)
    • Infectious Diseases Society of America; 1996 Jun 28-Feb 1 : Washington, DC. Alexandria, VA: Infectious Diseases Society of America for the Foundation for Retrovirology and Human Health
    • 3) [abstract 321]. In: Programs and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1996 Jun 28-Feb 1 : Washington, DC. Alexandria, VA: Infectious Diseases Society of America for the Foundation for Retrovirology and Human Health, 1996: 113
    • (1996) Programs and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections , pp. 113
    • Johnson, V.A.1    Quinn, J.B.2    Benoit, S.L.3
  • 13
    • 0029035638 scopus 로고
    • Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
    • 13. Boyer PL, Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995; 39: 1624-8
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 1624-1628
    • Boyer, P.L.1    Hughes, S.H.2
  • 14
    • 0030808934 scopus 로고    scopus 로고
    • Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials
    • 14. Wainberg MA. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. Leukemia 1997; 11 Suppl. 3): 85-8
    • (1997) Leukemia , Issue.11 SUPPL. 3 , pp. 85-88
    • Wainberg, M.A.1
  • 15
    • 0028783393 scopus 로고
    • Mitochondrial toxicity - New adverse drug effects
    • 15. Swartz MN. Mitochondrial toxicity - new adverse drug effects. N Engl J Med 1995; 333: 1146-8
    • (1995) N Engl J Med , vol.333 , pp. 1146-1148
    • Swartz, M.N.1
  • 16
    • 0026651622 scopus 로고
    • Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases α, β, and γ
    • 16. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases α, β, and γ. Antimicrob Agents Chemother 1992; 36: 1688-94
    • (1992) Antimicrob Agents Chemother , vol.36 , pp. 1688-1694
    • Hart, G.J.1    Orr, D.C.2    Penn, C.R.3
  • 17
    • 0030899204 scopus 로고    scopus 로고
    • Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection
    • 17. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997; 53 (4): 657-80
    • (1997) Drugs , vol.53 , Issue.4 , pp. 657-680
    • Perry, C.M.1    Faulds, D.2
  • 18
    • 0026471558 scopus 로고
    • Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells
    • 18. Sommadossi JP, Schinazi RF, Chu CK, Xie MY. Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells. Biochem Pharmacol 1992; 44: 1921-5
    • (1992) Biochem Pharmacol , vol.44 , pp. 1921-1925
    • Sommadossi, J.P.1    Schinazi, R.F.2    Chu, C.K.3    Xie, M.Y.4
  • 19
    • 0029563673 scopus 로고
    • Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter
    • Dec 21
    • 19. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter. N Engl J Med 1995 Dec 21; 333 (25): 1662-9
    • (1995) N Engl J Med , vol.333 , Issue.25 , pp. 1662-1669
    • Eron, J.J.1    Benoit, S.L.2    Jemsek, J.3
  • 20
    • 0030215471 scopus 로고    scopus 로고
    • Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection
    • Aug 1
    • 20. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med 1996 Aug 1; 125 (3): 161-72
    • (1996) Ann Intern Med , vol.125 , Issue.3 , pp. 161-172
    • Bartlett, J.A.1    Benoit, S.L.2    Johnson, V.A.3
  • 21
    • 8944225025 scopus 로고    scopus 로고
    • Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviralnaive patients: A randomized controlled comparison with zidovudine monotherapy
    • Jul 10
    • 21. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviralnaive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996 Jul 10; 276 (2): 118-25
    • (1996) JAMA , vol.276 , Issue.2 , pp. 118-125
    • Katlama, C.1    Ingrand, D.2    Loveday, C.3
  • 22
    • 8944245852 scopus 로고    scopus 로고
    • Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: A randomized controlled comparison with zidovudine monotherapy
    • Jul 10
    • 22. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996 Jul 10; 276 (2): 111-7
    • (1996) JAMA , vol.276 , Issue.2 , pp. 111-117
    • Staszewski, S.1    Loveday, C.2    Picazo, J.J.3
  • 23
    • 0030979361 scopus 로고    scopus 로고
    • Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the international AIDS society - USA Panel
    • Jun 25
    • 23. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997 Jun 25; 277 (24): 1962-9
    • (1997) JAMA , vol.277 , Issue.24 , pp. 1962-1969
    • Carpenter, C.C.J.1    Fischl, M.A.2    Hammer, S.M.3
  • 24
    • 0030997937 scopus 로고    scopus 로고
    • Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
    • May 17
    • 24. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997 May 17; 349: 1413-21
    • (1997) Lancet , vol.349 , pp. 1413-1421
  • 25
    • 0002461446 scopus 로고    scopus 로고
    • Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy
    • American Society of Microbiology; 1997Sep 28-Oct 1: Toronto. Washington, DC: American Society of Microbiology
    • 25. Saag M, Knowles M, Chang Y, et al. Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy [abstract I-101]. In: Program and Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy; American Society of Microbiology; 1997Sep 28-Oct 1: Toronto. Washington, DC: American Society of Microbiology, 1997: 261-2
    • (1997) Program and Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy , pp. 261-262
    • Saag, M.1    Knowles, M.2    Chang, Y.3
  • 26
    • 0442268112 scopus 로고    scopus 로고
    • A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
    • 26. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
    • (1997) N Engl J Med , vol.337 , pp. 725-733
    • Hammer, S.M.1    Squires, K.E.2    Hughes, M.D.3
  • 27
    • 0030869269 scopus 로고    scopus 로고
    • Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
    • 27. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9
    • (1997) N Engl J Med , vol.337 , pp. 734-739
    • Gulick, R.M.1    Mellors, J.W.2    Havlir, D.3
  • 28
    • 0013482777 scopus 로고    scopus 로고
    • Combivir™, a fixed dose formulation of lamivudine (3TC) 150 mg and zidovudine (ZDV) 300 mg, given BID plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV 200 mg TID plus a PI
    • Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health
    • 28. Eron J, Yetzer E, Poertz D, et al. Combivir™, a fixed dose formulation of lamivudine (3TC) 150 mg and zidovudine (ZDV) 300 mg, given BID plus a protease inhibitor (PI) compared to 3TC 150 mg BID and ZDV 200 mg TID plus a PI [abstract no. 387c]. In: Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1998: 151
    • (1998) Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections , pp. 151
    • Eron, J.1    Yetzer, E.2    Poertz, D.3
  • 29
    • 0013480903 scopus 로고    scopus 로고
    • Phase 3 study of the antiviral activity of AZT and 3TC given as separate regimens versus a new fixed dose combination (combivir™)
    • Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health
    • 29. Rozenbaum W, Chauveau E. Phase 3 study of the antiviral activity of AZT and 3TC given as separate regimens versus a new fixed dose combination (Combivir™) [abstract no. 669]. In: Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1998: 205
    • (1998) Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections , pp. 205
    • Rozenbaum, W.1    Chauveau, E.2
  • 30
    • 0030567824 scopus 로고    scopus 로고
    • Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
    • 30. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91
    • (1996) Lancet , vol.348 , pp. 283-291
  • 31
    • 10144244674 scopus 로고    scopus 로고
    • A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
    • 31. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335 (15): 1081-90
    • (1996) N Engl J Med , vol.335 , Issue.15 , pp. 1081-1090
    • Hammer, S.M.1    Katzenstein, D.A.2    Hughes, M.D.3
  • 32
    • 0030862080 scopus 로고    scopus 로고
    • Alteration of the dismal natural history of fibrosing choleostatic hepatitis secondary to hepatitis B virus with the use of lamivudine
    • 32. Al Faraidy K, Yoshida EM, Davis JE, et al. Alteration of the dismal natural history of fibrosing choleostatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64 (6): 926-8
    • (1997) Transplantation , vol.64 , Issue.6 , pp. 926-928
    • Al Faraidy, K.1    Yoshida, E.M.2    Davis, J.E.3
  • 33
    • 0029591574 scopus 로고
    • A preliminary trial of lamivudine for chronic hepatitis B infection
    • Dec 21
    • 33. Deinstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995 Dec 21; 333 (25): 1657-61
    • (1995) N Engl J Med , vol.333 , Issue.25 , pp. 1657-1661
    • Deinstag, J.L.1    Perrillo, R.P.2    Schiff, E.R.3
  • 34
    • 0031021902 scopus 로고    scopus 로고
    • Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
    • Jan
    • 34. Lai C-L, ChingC-K, Tung AK-M, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997 Jan; 25 (1): 241-4
    • (1997) Hepatology , vol.25 , Issue.1 , pp. 241-244
    • Lai, C.-L.1    Ching, C.-K.2    Tung, A.K.-M.3
  • 35
    • 0030772798 scopus 로고    scopus 로고
    • Lamivudine therapy for chronic hepatitis B - A six-month randomized dose-ranging study
    • Oct
    • 35. Nevens F, Main J, Hoonkoop P, et al. Lamivudine therapy for chronic hepatitis B - a six-month randomized dose-ranging study. Gastroenterology 1997 Oct; 113 (4): 1258-63
    • (1997) Gastroenterology , vol.113 , Issue.4 , pp. 1258-1263
    • Nevens, F.1    Main, J.2    Hoonkoop, P.3
  • 36
    • 0030989328 scopus 로고    scopus 로고
    • Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B
    • 36. Vanthiel DH, Friedlander L, Kania RJ, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 1997; 44 (15): 808-12
    • (1997) Hepatogastroenterology , vol.44 , Issue.15 , pp. 808-812
    • Vanthiel, D.H.1    Friedlander, L.2    Kania, R.J.3
  • 37
    • 0031037065 scopus 로고    scopus 로고
    • Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
    • 37. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B -virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2
    • (1997) Lancet , vol.349 , pp. 20-22
    • Bartholomew, M.M.1    Jansen, R.W.2    Jeffers, L.J.3
  • 38
    • 0031780935 scopus 로고    scopus 로고
    • Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
    • 38. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27 (6): 1670-7
    • (1998) Hepatology , vol.27 , Issue.6 , pp. 1670-1677
    • Allen, M.I.1    Deslauriers, M.2    Andrews, C.W.3
  • 39
    • 0028575676 scopus 로고
    • Interspecies scaling and pharmacokinetic parameters of 3TC in humans
    • Oct
    • 39. Hussey EK, Donn KH, Daniel MJ, et al. Interspecies scaling and pharmacokinetic parameters of 3TC in humans. J Clin Pharmacol 1994 Oct; 34: 975-7
    • (1994) J Clin Pharmacol , vol.34 , pp. 975-977
    • Hussey, E.K.1    Donn, K.H.2    Daniel, M.J.3
  • 40
    • 0027074279 scopus 로고
    • The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study
    • Dec
    • 40. van Leeuwen R, Lange JMA, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992 Dec; 6: 1417-25
    • (1992) AIDS , vol.6 , pp. 1417-1425
    • Van Leeuwen, R.1    Lange, J.M.A.2    Hussey, E.K.3
  • 41
    • 0029591139 scopus 로고
    • Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine
    • Dec
    • 41. Yuen GJ, Morris DM, Mydlow PK, et al. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995 Dec; 35: 1174-80
    • (1995) J Clin Pharmacol , vol.35 , pp. 1174-1180
    • Yuen, G.J.1    Morris, D.M.2    Mydlow, P.K.3
  • 42
    • 0031831657 scopus 로고    scopus 로고
    • Single-dose pharmacokinetics of lamivudine in subjects with impaired renal function and effect of haemodialysis
    • 42. Johnson MA, Verpooten GA, Daniel MJ, et al. Single-dose pharmacokinetics of lamivudine in subjects with impaired renal function and effect of haemodialysis. Br J Clin Pharmacol 1998; 46: 21-7
    • (1998) Br J Clin Pharmacol , vol.46 , pp. 21-27
    • Johnson, M.A.1    Verpooten, G.A.2    Daniel, M.J.3
  • 43
    • 0003979209 scopus 로고    scopus 로고
    • Glaxo Wellcome Incorporated
    • 43. Data on file. Glaxo Wellcome Incorporated
    • Data on File
  • 44
    • 0013482691 scopus 로고    scopus 로고
    • Bioequivalence of combivir™ tablet and epivir® plus retrovir tablets
    • Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health
    • 44. Moore KHP, Lloyd PP, Duncan B, et al. Bioequivalence of Combivir™ tablet and Epivir® plus Retrovir tablets [abstract no. 671]. In: Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Infectious Diseases Society of America; 1998 Feb 1-5: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1998: 205
    • (1998) Programs and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections , pp. 205
    • Moore, K.H.P.1    Lloyd, P.P.2    Duncan, B.3
  • 45
    • 0029900659 scopus 로고    scopus 로고
    • Pharmacokinetics of lamivudine administered alone and with trimethoprimsulfamethoxazole
    • May
    • 45. Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprimsulfamethoxazole. Clin Pharmacol Ther 1996 May; 59 (5): 550-8
    • (1996) Clin Pharmacol Ther , vol.59 , Issue.5 , pp. 550-558
    • Moore, K.H.1    Yuen, G.J.2    Raasch, R.H.3
  • 46
    • 0027216366 scopus 로고
    • Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients
    • Aug
    • 46. Angel JB, Hussey EK, Hall ST, et al. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Drug Invest 1993 Aug; 6: 70-4
    • (1993) Drug Invest , vol.6 , pp. 70-74
    • Angel, J.B.1    Hussey, E.K.2    Hall, S.T.3
  • 47
    • 0029952016 scopus 로고    scopus 로고
    • Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction
    • 47. Heald AE, Hsyu PH, Yuen GJ, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996; 40 (6): 1514-8
    • (1996) Antimicrob Agents Chemother , vol.40 , Issue.6 , pp. 1514-1518
    • Heald, A.E.1    Hsyu, P.H.2    Yuen, G.J.3
  • 48
    • 0031818475 scopus 로고    scopus 로고
    • The pharmacokinetics of lamivudine in patients with impaired hepatic function
    • 48. Johnson MA, Horak J, Breuel PB. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol 1998; 54: 363-6
    • (1998) Eur J Clin Pharmacol , vol.54 , pp. 363-366
    • Johnson, M.A.1    Horak, J.2    Breuel, P.B.3
  • 49
    • 0028356833 scopus 로고
    • High-performance liquid chromatographic assay for (-)-2′-deoxy-3′-thiacytidine in human serum
    • Jul 1
    • 49. Harker AJ, Evans GL, Hawley AE, Morris DM. High-performance liquid chromatographic assay for (-)-2′-deoxy-3′-thiacytidine in human serum. J Chromatogr B: Biomed Appl 1994 Jul 1; 657 (1): 227-32
    • (1994) J Chromatogr B: Biomed Appl , vol.657 , Issue.1 , pp. 227-232
    • Harker, A.J.1    Evans, G.L.2    Hawley, A.E.3    Morris, D.M.4
  • 50
    • 0028269179 scopus 로고
    • Determination of 2′-deoxy-3′-thiacytidine (3TC) in human urine by liquid chromatography: Direct injection with column switching
    • 50. Morris DM, Selinger K. Determination of 2′-deoxy-3′-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching. J Pharm Biomed Anal 1994; 12 (2):255-64
    • (1994) J Pharm Biomed Anal , vol.12 , Issue.2 , pp. 255-264
    • Morris, D.M.1    Selinger, K.2
  • 51
    • 0013557085 scopus 로고    scopus 로고
    • Analysis of potential gender differences in lamivudine (3TC) disposition using population pharmacokinetics from two Phase III clinical trials in HIV-infected patients
    • National Conference on Women and HIV; May 4-7: Los Angeles
    • 51. Moore KHP, Yuen GJ, Hussey EK. Analysis of potential gender differences in lamivudine (3TC) disposition using population pharmacokinetics from two Phase III clinical trials in HIV-infected patients [abstract 1298]. In: Abstract Book of the National Conference on Women and HIV; National Conference on Women and HIV; 1997 May 4-7: Los Angeles
    • (1997) Abstract Book of the National Conference on Women and HIV
    • Moore, K.H.P.1    Yuen, G.J.2    Hussey, E.K.3
  • 52
    • 0028997078 scopus 로고
    • A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection
    • 52. Pluda JM, Cooley TP, Montaner JSG, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171 (6): 1438-47
    • (1995) J Infect Dis , vol.171 , Issue.6 , pp. 1438-1447
    • Pluda, J.M.1    Cooley, T.P.2    Montaner, J.S.G.3
  • 53
    • 19244362628 scopus 로고    scopus 로고
    • Lamivudine in children with immunodeficiency virus infection: A phase I/II study
    • 53. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with immunodeficiency virus infection: a phase I/II study. J Infect Dis 1996; 174 (1): 16-25
    • (1996) J Infect Dis , vol.174 , Issue.1 , pp. 16-25
    • Lewis, L.L.1    Venzon, D.2    Church, J.3
  • 54
    • 0000312283 scopus 로고    scopus 로고
    • The pharmacokinetics of 3TC administered to HIV-1 infected women (pre-partum, during labour and post-partum) and their offspring
    • International AIDS Society; 1996 Jul 7-12: Vancouver: International AIDS Society
    • 54. Johnson MA, Goodwin C, Yuen GJ, et al. The pharmacokinetics of 3TC administered to HIV-1 infected women (pre-partum, during labour and post-partum) and their offspring [abstract no. Tu.C.445]. In: Program and Abstracts of the 11th International Conference on AIDS; International AIDS Society; 1996 Jul 7-12: Vancouver: International AIDS Society, 1996: 249-50
    • (1996) Program and Abstracts of the 11th International Conference on AIDS , pp. 249-250
    • Johnson, M.A.1    Goodwin, C.2    Yuen, G.J.3
  • 55
    • 0026669787 scopus 로고
    • Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex
    • 55. Dudley MN, Graham K, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166: 480-5
    • (1992) J Infect Dis , vol.166 , pp. 480-485
    • Dudley, M.N.1    Graham, K.2    Kaul, S.3
  • 56
    • 0028911385 scopus 로고
    • Clinical pharmacokinetics of nucleoside antiretroviral agents
    • 56. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995; 171: Suppl. 2: S99-112
    • (1995) J Infect Dis , vol.171 , Issue.SUPPL. 2
    • Dudley, M.N.1
  • 57
    • 0028948198 scopus 로고
    • Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase I/II study
    • May
    • 57. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995 May; 171: 1166-71
    • (1995) J Infect Dis , vol.171 , pp. 1166-1171
    • Van Leeuwen, R.1    Katlama, C.2    Kitchen, V.3
  • 58
    • 0028889357 scopus 로고
    • Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of non-human primates
    • Dec
    • 58. Blaney SM, Daniel MJ, Harker AJ, et al. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of non-human primates. Antimicrob Agents Chemother 1995 Dec; 39 (12): 2779-82
    • (1995) Antimicrob Agents Chemother , vol.39 , Issue.12 , pp. 2779-2782
    • Blaney, S.M.1    Daniel, M.J.2    Harker, A.J.3
  • 59
    • 0031723646 scopus 로고    scopus 로고
    • Pharmacokinetics and antiretroviral activity of lamividine alone or when co-administered with zidovudine in HIV-infected pregnant women and their offspring
    • 59. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamividine alone or when co-administered with zidovudine in HIV-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-33
    • (1998) J Infect Dis , vol.178 , pp. 1327-1333
    • Moodley, J.1    Moodley, D.2    Pillay, K.3
  • 60
    • 0000535079 scopus 로고
    • Pharmacokinetics of oral lamivudine administered alone and with oral zidovudine (ZDV) in asymptomatic patients with human immunodeficiency virus (HIV) infection
    • Feb
    • 60. Horton CM, Yuen G, Mikolich DM, et al. Pharmacokinetics of oral lamivudine administered alone and with oral zidovudine (ZDV) in asymptomatic patients with human immunodeficiency virus (HIV) infection [abstract no. PIII-64]. Clin Pharmacol Ther 1994 Feb; 55 (2): 198
    • (1994) Clin Pharmacol Ther , vol.55 , Issue.2 , pp. 198
    • Horton, C.M.1    Yuen, G.2    Mikolich, D.M.3
  • 61
    • 0030776777 scopus 로고    scopus 로고
    • Lamivudine (3TC) phosphorylation and drug interactions in vitro
    • 61. Kewn S, Veal GJ, Hoogard PC, et al. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol 1997; 54: 589-95
    • (1997) Biochem Pharmacol , vol.54 , pp. 589-595
    • Kewn, S.1    Veal, G.J.2    Hoogard, P.C.3
  • 62
    • 0028300765 scopus 로고
    • Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells
    • 62. Gao WY, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269 (17): 12633-8
    • (1994) J Biol Chem , vol.269 , Issue.17 , pp. 12633-12638
    • Gao, W.Y.1    Agbaria, R.2    Driscoll, J.S.3
  • 63
    • 0013515054 scopus 로고    scopus 로고
    • Pharmacokinetics of lamivudine in chronic hepatitis B virus-infected patients undergoing liver transplantation
    • American Society of Microbiology; 1997 Sep 28-Oct 1: Toronto. Washington, DC: American Society of Microbiology
    • 63. Johnson MA, Mutimer D, Ahmed M, et al. Pharmacokinetics of lamivudine in chronic hepatitis B virus-infected patients undergoing liver transplantation [abstract no. A-47]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; American Society of Microbiology; 1997 Sep 28-Oct 1: Toronto. Washington, DC: American Society of Microbiology, 1997: 9
    • (1997) Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy , pp. 9
    • Johnson, M.A.1    Mutimer, D.2    Ahmed, M.3
  • 64
    • 0029415188 scopus 로고
    • Renal disposition and drug interaction screening of (-)-2′-deoxy-3′-thiacytidine (3TC) in the isolated perfused rat kidney
    • Dec
    • 64. Sweeney KR, Hsyu P-H, Statkevich P, et al. Renal disposition and drug interaction screening of (-)-2′-deoxy-3′-thiacytidine (3TC) in the isolated perfused rat kidney. Pharmaceut Res 1995 Dec; 12(12): 1958-63
    • (1995) Pharmaceut Res , vol.12 , Issue.12 , pp. 1958-1963
    • Sweeney, K.R.1    Hsyu, P.-H.2    Statkevich, P.3
  • 65
    • 0013520977 scopus 로고
    • Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-infected individuals
    • American Society of Microbiology; 1994 Oct 4-7; Orlando (FL). Washington, DC: American Society of Microbiology
    • 65. Rana KZ, Horton CM, Yuen GJ, et al. Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-infected individuals [abstract no. A62]. In: Program and abstracts of the 34th Interscicnce Conference on Antimicrobial Agents and Chemotherapy; American Society of Microbiology; 1994 Oct 4-7; Orlando (FL). Washington, DC: American Society of Microbiology, 1994: 83
    • (1994) Program and Abstracts of the 34th Interscicnce Conference on Antimicrobial Agents and Chemotherapy , pp. 83
    • Rana, K.Z.1    Horton, C.M.2    Yuen, G.J.3
  • 66
    • 0001964670 scopus 로고    scopus 로고
    • The safety and pharmacokinetics of GW1592U89, zidovudine and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients
    • 66. Symonds WT, McDowell J, Chittick G, et al. The safety and pharmacokinetics of GW1592U89, zidovudine and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients [abstract]. AIDS 1996; 10 Suppl. 2: S23
    • (1996) AIDS , vol.10 , Issue.SUPPL. 2
    • Symonds, W.T.1    McDowell, J.2    Chittick, G.3
  • 67
    • 0032101831 scopus 로고    scopus 로고
    • Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study
    • 67. Mutimer D, Naoumov N, Honkoop P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28: 923-9
    • (1998) J Hepatol , vol.28 , pp. 923-929
    • Mutimer, D.1    Naoumov, N.2    Honkoop, P.3
  • 68
    • 0029869720 scopus 로고    scopus 로고
    • Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation
    • May
    • 68. Veal GJ, Hoggard PG, Barry MG, et al. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS 1996 May; 10 (5): 546-8
    • (1996) AIDS , vol.10 , Issue.5 , pp. 546-548
    • Veal, G.J.1    Hoggard, P.G.2    Barry, M.G.3
  • 69
    • 0000491105 scopus 로고
    • Phase II trial of lamivudine for chronic hepatitis B
    • 69. Tyrell DLJ, Mitchell MC, De Man RA, et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993; 18: 112(A)
    • (1993) Hepatology , vol.18
    • Tyrell, D.L.J.1    Mitchell, M.C.2    De Man, R.A.3
  • 70
    • 0032499913 scopus 로고    scopus 로고
    • A one year trial of lamivudine for chronic hepatitis B
    • 70. Lai CL, Chien RN, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998: 339 (2); 61-8
    • (1998) N Engl J Med , vol.339 , Issue.2 , pp. 61-68
    • Lai, C.L.1    Chien, R.N.2    Leung, N.W.Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.